TLDC2: A Potential Drug Target and Biomarker (G140711)

Target Name: TLDC2

NCBI ID: G140711

TLDC2

TLDC2: A Potential Drug Target and Biomarker

Abstract:

TLDC2 (TBC/LysM-associated domain containing 2) is a protein that has been identified as a potential drug target and biomarker. It plays a crucial role in various cellular processes, including cell signaling, DNA replication, and chromatin regulation. The identification and Characterization of TLDC2 as a drug target and biomarker make it an attractive target for drug development and research.

Introduction:

TLDC2 (TBC/LysM-associated domain containing 2) is a protein that is expressed in various cell types, including humans. It is a 21 kDa protein that contains a unique domain consisting of a TBC repeat and a LysM domain. The TBC repeat is a conserved protein motif that is found in various proteins, including DNA-binding proteins, while the LysM domain is a unique protein domain that is composed of a lysine residue, an imidazole ring, and a carboxylic acid residue.

Expressions and Functions:

TLDC2 is highly expressed in various tissues, including brain, heart, liver, and muscle. It is involved in various cellular processes, including cell signaling, DNA replication, and chromatin regulation. TLDC2 plays a crucial role in the regulation of DNA replication, as it is known to interact with the DNA replication machinery.

In addition to its role in DNA replication, TLDC2 is involved in cell signaling. It has been shown to interact with various signaling pathways, including the PI3K/Akt signaling pathway. This interaction between TLDC2 and the PI3K/Akt signaling pathway suggests that TLDC2 may be a potential drug target for the treatment of various diseases.

TLDC2 is also involved in chromatin regulation. It has been shown to interact with the chromatin-remodeling protein, PRDM1. This interaction between TLDC2 and PRDM1 suggests that TLDC2 may be a potential biomarker for the diagnosis and treatment of various diseases, including cancer.

Drug Development and target identification:

The identification of TLDC2 as a potential drug target makes it an attractive target for drug development. The development of small molecules that can interact with TLDC2 and modulate its activity can lead to the development of new treatments for various diseases.

One approach to identifying small molecules that can interact with TLDC2 is through the use of high-throughput screening assays, such as yeast two-hybrid (Y2H) assays or protein fragment complementation assays. These assays can identify small molecules that can interact with TLDC2 and modulate its activity.

Another approach to identifying small molecules that can interact with TLDC2 is through the use of computational tools, such as molecular docking and molecular dynamics simulations. These tools can predict the binding of small molecules to TLDC2 and identify potential binding sites.

Conclusion:

TLDC2 is a protein that has been identified as a potential drug target and biomarker. Its role in various cellular processes, including cell signaling and chromatin regulation, makes it an attractive target for drug development. The identification and characterization of TLDC2 as a potential drug target and biomarker make it an exciting area of 鈥嬧?媟esearch. Further studies are needed to fully understand the mechanisms of TLDC2 and its potential as a drug target and biomarker.

Protein Name: TBC/LysM-associated Domain Containing 2

The "TLDC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TLDC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets